Plenity-V (MC0979 / GS110)
Gelesis SRL · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K261783, Plenity-V (MC0979/GS110), on October 2, 2026, with the applicant listed as Gelesis SRL and product code QFQ under 21 CFR 876.5982. The submission is a traditional 510(k), so the decision is a clearance rather than a PMA approval. The summary describes Plenity-V as identical to the cleared predicate Plenity (K230133) in technological characteristics and mechanism of action, with the change limited to the capsule: a transparent HPMC capsule of the same size replaces the white porcine gelatin capsule.
The stated rationale is that the change replaces an animal-derived component with a plant-based material and removes titanium dioxide, and the summary reports no nonclinical or bench studies conducted specifically for the capsule material change. The summary also states that stability work was performed on Plenity pods with a comparison said to apply to Plenity-V blisters, and that a multi-lot Plenity-V stability study is ongoing to confirm a 30-month shelf life. The source does not provide the review basis for the decision or independent confirmation of the sponsor's equivalence and safety statements.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261783
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Gelesis SRL
- Product code
- QFQ
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ingested, Transient, Space Occupying Device For Weight Management And/Or Weight Loss.
- Applicant
- Gelesis SRL
- Product code
- QFQ
- FDA device class
- 2
FDA decision timeline
K261783 received
Application receipt date recorded by FDA.
K261783 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Gelesis SRL
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Calimera
Sources and methodology
- Original FDA record: K261783
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records